Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.
Stephen Brannan, MD
Advertisement
Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Articles by Stephen Brannan, MD
Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences
2
Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases
3
Sleep as Connective Tissue: Quantifying Team Dynamics in Elite Sports
4
A Moral Injury Update: The PNHP Study and an Imminent Step Toward Peace in the Mideast
5
